Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
BACKGROUND: We investigated prognostic factors (PFs) for 90-day mortality in a large cohort of advanced/metastatic soft tissue sarcoma (STS) patients treated with first-line chemotherapy. - METHODS: The PFs were identified by both logistic regression analysis and probability tree analysis in patient...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
19 April 2011
|
| In: |
British journal of cancer
Year: 2011, Volume: 104, Issue: 10, Pages: 1544-1550 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/bjc.2011.136 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bjc.2011.136
|
| Author Notes: | N. Penel, M.V. Glabbeke, S. Mathoulin-Pelissier, I. Judson, S. Sleijfer, B. Bui, P. Schoffski, M. Ouali, S. Marreaud, V. Brouste, A. Duhamel, P. Hohenberger and J.-Y. Blay |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1819349624 | ||
| 003 | DE-627 | ||
| 005 | 20230710110509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221019s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/bjc.2011.136 |2 doi | |
| 035 | |a (DE-627)1819349624 | ||
| 035 | |a (DE-599)KXP1819349624 | ||
| 035 | |a (OCoLC)1389766709 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Penel, Nicolas |e VerfasserIn |0 (DE-588)1259541037 |0 (DE-627)1806746859 |4 aut | |
| 245 | 1 | 0 | |a Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma |b the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study |c N. Penel, M.V. Glabbeke, S. Mathoulin-Pelissier, I. Judson, S. Sleijfer, B. Bui, P. Schoffski, M. Ouali, S. Marreaud, V. Brouste, A. Duhamel, P. Hohenberger and J.-Y. Blay |
| 264 | 1 | |c 19 April 2011 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.10.2022 | ||
| 520 | |a BACKGROUND: We investigated prognostic factors (PFs) for 90-day mortality in a large cohort of advanced/metastatic soft tissue sarcoma (STS) patients treated with first-line chemotherapy. - METHODS: The PFs were identified by both logistic regression analysis and probability tree analysis in patients captured in the Soft Tissue and Bone Sarcoma Group (STBSG) database (3002 patients). Scores derived from the logistic regression analysis and algorithms derived from probability tree analysis were subsequently validated in an independent study cohort from the French Sarcoma Group (FSG) database (404 patients). - RESULTS: The 90-day mortality rate was 8.6 and 4.5% in both cohorts. The logistic regression analysis retained performance status (PS; odds ratio (OR)=3.83 if PS=1, OR=12.00 if PS ≥2), presence of liver metastasis (OR=2.37) and rare site metastasis (OR=2.00) as PFs for early death. The CHAID analysis retained PS as a major discriminator followed by histological grade (only for patients with PS ≥2). In both models, PS was the most powerful PF for 90-day mortality. - CONCLUSION: Performance status has to be taken into account in the design of further clinical trials and is one of the most important parameters to guide patient management. For those patients with poor PS, expected benefits from therapy should be weighed up carefully against the anticipated toxicities. | ||
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Cohort Studies | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Logistic Models | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Risk Factors | |
| 650 | 4 | |a Sarcoma | |
| 650 | 4 | |a Soft Tissue Neoplasms | |
| 650 | 4 | |a Treatment Outcome | |
| 700 | 1 | |a Glabbeke, M. V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mathoulin-Pelissier, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Judson, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sleijfer, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bui, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schoffski, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ouali, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marreaud, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brouste, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Duhamel, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hohenberger, Peter |d 1953- |e VerfasserIn |0 (DE-588)1025311469 |0 (DE-627)72202875X |0 (DE-576)370195574 |4 aut | |
| 700 | 1 | |a Blay, J.-Y. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d Edinburgh : Nature Publ. Group, 1947 |g 104(2011), 10, Seite 1544-1550 |h Online-Ressource |w (DE-627)320420094 |w (DE-600)2002452-6 |w (DE-576)103746854 |x 1532-1827 |7 nnas |a Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study |
| 773 | 1 | 8 | |g volume:104 |g year:2011 |g number:10 |g pages:1544-1550 |g extent:7 |a Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study |
| 856 | 4 | 0 | |u https://doi.org/10.1038/bjc.2011.136 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221019 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 1025311469 |a Hohenberger, Peter |m 1025311469:Hohenberger, Peter |d 60000 |d 61800 |e 60000PH1025311469 |e 61800PH1025311469 |k 0/60000/ |k 1/60000/61800/ |p 12 | ||
| 999 | |a KXP-PPN1819349624 |e 4199185372 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"subtitle":"the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study","title_sort":"Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma","title":"Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma"}],"name":{"displayForm":["N. Penel, M.V. Glabbeke, S. Mathoulin-Pelissier, I. Judson, S. Sleijfer, B. Bui, P. Schoffski, M. Ouali, S. Marreaud, V. Brouste, A. Duhamel, P. Hohenberger and J.-Y. Blay"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"7 S."}],"language":["eng"],"recId":"1819349624","note":["Gesehen am 19.10.2022"],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Penel, Nicolas","family":"Penel","given":"Nicolas"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Glabbeke, M. V.","given":"M. V.","family":"Glabbeke"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Mathoulin-Pelissier, S.","family":"Mathoulin-Pelissier","given":"S."},{"family":"Judson","given":"I.","display":"Judson, I.","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Sleijfer, S.","given":"S.","family":"Sleijfer"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Bui, B.","family":"Bui","given":"B."},{"roleDisplay":"VerfasserIn","role":"aut","display":"Schoffski, P.","given":"P.","family":"Schoffski"},{"family":"Ouali","given":"M.","role":"aut","roleDisplay":"VerfasserIn","display":"Ouali, M."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Marreaud, S.","given":"S.","family":"Marreaud"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Brouste, V.","given":"V.","family":"Brouste"},{"given":"A.","family":"Duhamel","display":"Duhamel, A.","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Hohenberger, Peter","given":"Peter","family":"Hohenberger"},{"given":"J.-Y.","family":"Blay","display":"Blay, J.-Y.","roleDisplay":"VerfasserIn","role":"aut"}],"id":{"doi":["10.1038/bjc.2011.136"],"eki":["1819349624"]},"origin":[{"dateIssuedDisp":"19 April 2011","dateIssuedKey":"2011"}],"relHost":[{"id":{"zdb":["2002452-6"],"eki":["320420094"],"issn":["1532-1827"]},"origin":[{"dateIssuedDisp":"1947-","publisher":"Nature Publ. Group ; Churchill Livingstone","publisherPlace":"Edinburgh ; Edinburgh","dateIssuedKey":"1947"}],"part":{"year":"2011","extent":"7","volume":"104","pages":"1544-1550","text":"104(2011), 10, Seite 1544-1550","issue":"10"},"pubHistory":["Volume 1, issue 1 (1 March 1947)-"],"titleAlt":[{"title":"BJC"}],"title":[{"title_sort":"British journal of cancer","title":"British journal of cancer","subtitle":"BJC"}],"note":["Gesehen am 27.10.25"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"recId":"320420094","type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) studyBritish journal of cancer"}]} | ||
| SRT | |a PENELNICOLPERFORMANC1920 | ||